Galenica AG
Galenica AG is a leading healthcare services company serving the Swiss market and international clients. Headquartered in Bern, Switzerland, the company was founded in 1927. Its operations are organized into two principal divisions. The segment "Products & Care" oversees an extensive network of 520 pharmacies,…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
1D
+0.6%
1W
+2.9%
1M
+6.6%
6M
-2.5%
YTD
-10.2%
1Y
-2.1%
2Y
+16.5%
5Y
+29.5%
10Y
–
Next earnings date
09/03/2027 (in 143 days)
Volatility around earnings
~34% stronger price swings than usual
Pattern detected by the Market Jury detector vrange-breakout-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Range breakout
BullishThe price has broken out of a longer sideways range (support and resistance) to the upside or downside. In technical analysis, this is read as a signal that a new trend is starting in the breakout direction.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
P/E
27.49
P/B
3.1
EV/EBITDA
15.64
RETURN ON EQUITY
4.7%
NET MARGIN
3.1%
DEBT/EQUITY
0.8
DIVIDEND YIELD
2.9%
AS OF
30/06/2026
FREE FLOAT
99.9%
FLOAT SHARES
49,760,758
AVG. DAILY VOLUME (30D)
86,703
Galenica AG is a company in the Healthcare sector, Medical - Distribution industry, headquartered in Switzerland.
The CEO is Marc Werner, the company employs around 6,623 people.
The IPO was on 07/04/2017; the stock trades on SIX under the ticker GALE.SW.
The next earnings date is 09/03/2027.
Around past earnings, price swings were roughly 34% stronger than usual.
Yes. The last dividend was CHF 2.50 per share, ex-date 23/04/2026, paid on 27/04/2026.
The dividend yield is 2.9% (as of 30/06/2026).
Comparable stocks include DocMorris, McKesson, Cencora, Cardinal Health, Henry Schein, Roche Holding, BeOne Medicines and Sandoz Group.
Clicking "Analyze stock" lets five strategies assess Galenica against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.